Information:
Error:
ID
34325
Description
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01754974
Link
https://clinicaltrials.gov/show/NCT01754974
Keywords
Versions (1)
- 1/16/19 1/16/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 16, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Hepatitis C Virus (HCV) NCT01754974
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
chronic hepatitis c, genotype 1
boolean
ID.2
Item
hcv rna ≥100,000 iu/ml at screening
boolean
ID.3
Item
liver biopsy documenting no cirrhosis (within prior 3 years). where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease
boolean
ID.4
Item
naïve to prior anti-hcv therapy
boolean
ID.5
Item
infected with hcv other than genotype 1
boolean
ID.6
Item
positive hepatitis b surface antigen (hbsag), or human immunodeficiency virus (hiv)-1/hiv-2 antibody at screening
boolean
ID.7
Item
evidence of liver disease other than hcv
boolean
ID.8
Item
active substance abuse
boolean
ID.9
Item
use of hematologic growth factors within 90 days prior to study randomization
boolean
ID.10
Item
evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria
boolean